Lupus nephritis, or systemic lupus erythematosus (SLE) with renal involvement, is an autoimmune disease in which inflammatory changes develop in the renal structures. This condition is caused by the formation of antibodies to the body's own cells, which leads to tissue damage, including the glomeruli of the kidneys. Lupus nephritis is characterized by a variety of clinical manifestations, including edema, hypertension, proteinuria, and possible development of renal failure. Disease progression can significantly worsen the quality of life of patients and requires a comprehensive approach to diagnosis and therapy, which makes this disease a topical issue for the medical community.
History of the disease and interesting historical facts
Systemic lupus erythematosus was first described in medical literature in the 19th century. In 1851, English physician Dr. William Osler published observations of patients with manifestations similar to SLE, but the exact connection between lupus and kidney damage was not established until later. In the 1940s, the molecules responsible for autoimmune reactions became known, which opened up new horizons for the diagnosis and treatment of lupus nephritis. An interesting fact is that the name "lupus" comes from the Latin word "lupus", meaning "wolf", due to the similarity of the skin rash to wolf bites. Research shows that lupus nephritis has been actively studied for over 100 years, and work continues to understand and combat it.
Epidemiology
Lupus nephritis occurs in 30-50% patients with systemic lupus erythematosus and is diagnosed more often in women than in men at a ratio of 9:1. According to studies, the highest prevalence is observed in African American and Hispanic populations. According to data from different populations, the incidence varies from 1.5 to 25 cases per 100,000 population annually. Given the potential complications such as renal failure, monitoring the incidence is important for public health. According to recent data, more than 10% patients with lupus nephritis experience the development of end-stage renal disease, which significantly reduces the life expectancy and quality of life of patients.
Genetic predisposition to this disease
There is evidence of a hereditary predisposition to systemic lupus erythematosus and lupus nephritis. Studies have identified several genes associated with an increased risk of developing the disease. The most significant of these include the HLA-DRB1 gene, which is associated with autoimmune diseases, and apoptosis genes such as FAS. Also, genes responsible for the synthesis of interferons play a key role in the pathogenesis of SLE. In recent years, genetic studies have been conducted to identify SNPs (single nucleotide polymorphisms) that may be associated with the development of lupus nephritis. Thus, understanding the genetic predisposition will improve diagnostics and create new treatment strategies for patients with an increased risk.
Risk factors for the development of this disease
Risk factors that contribute to the development of lupus nephritis include both physical and chemical ones. Physical factors include:
- Weather conditions (solar radiation, which can provoke an exacerbation of the disease);
- Injuries and infections that weaken the immune response.
Chemical factors may include:
- Estrogens, which have an effect on autoimmune processes;
- Some medications, such as antihypertensive drugs, may trigger the development of lupus in susceptible individuals.
Additionally, other possible associated factors include:
- Stressful situations that can contribute to an exacerbation of the disease;
- The presence of infectious diseases (eg, HPV), indicating possible mechanisms that contribute to the formation of an autoimmune response.
Diagnosis of this disease
Diagnosis of lupus nephritis is based on a combination of clinical presentation and laboratory data. The main symptoms include:
- Swelling, especially in the lower extremities;
- Increased blood pressure;
- General weakness and fatigue;
- Proteinuria and hematuria.
Laboratory tests show the presence of anti-DS DNA antibodies, which is specific for lupus. In addition, complement assays (C3 and C4) may help assess disease activity. Radiologic examinations (eg, renal ultrasound) may show changes in kidney structure that are characteristic of an inflammatory process. Differential diagnosis includes exclusion of other kidney diseases, such as glomerulonephritis or diabetic nephropathy.
Treatment
Treatment of lupus nephritis requires a comprehensive approach and includes several areas. Initially, general treatment is used, including rest and lifestyle adjustments. Pharmacological treatment may include:
- Corticosteroids used to reduce the inflammatory response;
- Immunosuppressants (eg, azathioprine, mycophenolate mofetil) used to control immune processes;
- Antidepressants that remind the patient of the psycho-emotional state.
In some cases, surgical intervention may be required, for example, in the case of renal failure or significant anatomical changes that threaten the patient's life. Thanks to modern methods and approaches, the treatment of lupus nephritis is becoming more effective, aimed at reducing the activity of the disease and maintaining the quality of life of patients.
List of medications used to treat this disease
The following groups of drugs are used in the treatment of lupus nephritis:
- Corticosteroids (prednisolone, methylprednisolone);
- Immunosuppressants (azathioprine, cyclosporine, mycophenolate mofetil);
- Nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac);
- Biological therapy (romilkizumab, bellaton);
- Anticoagulants, if there is thrombus formation (warfarin).
Disease monitoring
Control stages of monitoring volvulus nephritis include regular assessment of the functional state of the kidneys, which allows for timely detection of possible complications. The prognosis depends on the timeliness of diagnosis and initiation of treatment; most patients can achieve remission. However, there is a risk of relapse. Complications may include deterioration of kidney function, development of cardiovascular diseases and a significant decrease in quality of life.
Age-related features of the disease
Lupus nephritis exhibits different clinical features depending on the patient's age. In young women (20-30 years old), the disease often occurs in a more aggressive form with rapid development of nephritis. In elderly patients, the disease is often observed in a less pronounced form. SLE with kidney damage also occurs in children, but the progression may be different, often requiring a different approach to treatment and monitoring.
Questions and Answers
- What are the main symptoms of lupus nephritis? The main symptoms include edema, high blood pressure, proteinuria and general weakness.
- How is lupus nephritis diagnosed? Diagnosis includes clinical examination, laboratory tests for specific antibodies and ultrasound of the kidneys.
- What is the treatment for lupus nephritis? Treatment may include corticosteroids, immunosuppressants, NSAIDs, and, if necessary, surgery.
- What are the risk factors for lupus nephritis? Risk factors include genetic predisposition, physical factors such as sun exposure, and certain chemicals.
- How often should lupus nephritis be monitored? Regular monitoring every 3-6 months is recommended to monitor kidney function and overall disease status.
Advice from Dr. Oleg Korzhikov
Oleg Korzhikov, an experienced nephrologist, recommends that those who experience symptoms such as swelling and fatigue should not delay a visit to the doctor. He emphasizes the importance of regularly monitoring the condition of the kidneys and keeping a diary of well-being, which can greatly help the doctor in diagnosis and treatment. The doctor also strongly advises avoiding excessive sun exposure and, if necessary, using sunscreen, as sunlight can exacerbate the course of the disease. Emphasizing that the right approach to nutrition and lifestyle is a key aspect in the control of lupus nephritis, he recommended a balanced diet, high antioxidant content and physical activity within reasonable limits.
